For the past year, a cerebral photobio-modulation system using light waves has been used at the Brainmoove center as a complement to care, in order to stimulate cerebral plasticity and have an impact on the cognitive level.
As in the article below, many effects are currently observed both cognitively and neurologically.
https://pubmed.ncbi.nlm.nih.gov/21182447
Notre Temps, April 9, 2021
"A clinical trial aimed at slowing the progression of Parkinson's disease was launched, after the" successful "operation of a first patient who had a brain implant that diffuses near infrared light, announced (…) the Grenoble University Hospital and the Atomic Energy Commission (CEA)”, reports Notre Temps.
"This new therapeutic approach, which has been proven in laboratory on animals, 'could slow the loss of motor functions in patients' suffering from Parkinson's disease, a neurodegenerative pathology which affects more than 6.5 million of people worldwide and which we cannot cure", specify the CHU and the CEA.
"A new technology, developed for several years at the experimental level, consists in 'delivering light near infrared (a specific range of wavelengths, NDLR) near the area of the brain which degenerates'", explains Prof. Stephan Chabardès from the University of Grenoble Alpes.
"In mice, rats and monkeys, this infrared has been shown to have significant effects on slowing down the cell death of neurons involved in the disease", continues this neurosurgeon at University Hospital of Grenoble Alpes.
“The CEA, the University Hospital of Grenoble Alpes, the University of Grenoble Alpes and Boston Scientific Corporation, a company specializing in medical devices, have therefore developed a probe which, once implanted in the human brain, is capable of delivering this infrared light. Without being too invasive", indicates Notre Temps.
"Unlike deep brain stimulation, which delivers an electric current, near infrared illumination targets the substantia nigra in the brain, the site of degeneration of neurons responsible for symptoms of the disease", the magazine explains.
"By illuminating the dark substance, the photons of light would act on the suffering cells, as if they were giving them back energy," he explains. Even if "it worked on animals (...) we must remain careful", nuance Professor Chabardès.
"The research team wants to include 14 patients in the protocol, lasting 4 years", concludes Notre Temps.
Article posté le 17/04/2021
consulter tous les articles de la thématique Parkinson